179 related articles for article (PubMed ID: 33486611)
1. LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway.
Wang X; Zhang Y; Zheng J; Yao C; Lu X
Cancer Immunol Immunother; 2021 Aug; 70(8):2235-2245. PubMed ID: 33486611
[TBL] [Abstract][Full Text] [Related]
2. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Wang QM; Lian GY; Song Y; Huang YF; Gong Y
Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
[TBL] [Abstract][Full Text] [Related]
3. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA UCA1 promotes anaplastic thyroid cancer cell proliferation via miR‑135a‑mediated c‑myc activation.
Wang Y; Hou Z; Li D
Mol Med Rep; 2018 Sep; 18(3):3068-3076. PubMed ID: 30015867
[TBL] [Abstract][Full Text] [Related]
5. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
[TBL] [Abstract][Full Text] [Related]
6. LncRNA
Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
[TBL] [Abstract][Full Text] [Related]
7. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
[No Abstract] [Full Text] [Related]
8. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
Gou L; Zou H; Li B
Cancer Biol Ther; 2019; 20(11):1355-1365. PubMed ID: 31500506
[TBL] [Abstract][Full Text] [Related]
10. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
[TBL] [Abstract][Full Text] [Related]
11. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
Yan P; Su Z; Zhang Z; Gao T
Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1/ miR-142-5p/ PD-L1 axis.
Jiang Y; Wang K; Lu X; Wang Y; Chen J
Mol Immunol; 2021 Dec; 140():47-58. PubMed ID: 34653794
[TBL] [Abstract][Full Text] [Related]
13. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
14. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
Bastman JJ; Serracino HS; Zhu Y; Koenig MR; Mateescu V; Sams SB; Davies KD; Raeburn CD; McIntyre RC; Haugen BR; French JD
J Clin Endocrinol Metab; 2016 Jul; 101(7):2863-73. PubMed ID: 27045886
[TBL] [Abstract][Full Text] [Related]
16. LncRNA H19 Influences Cellular Activities via the miR-454-3p/BHLHE40 Axis in Anaplastic Thyroid Carcinoma.
Wu Y; Yang J; Zhang H; Cheng J; Lei P; Huang J
Horm Metab Res; 2024 May; 56(5):392-399. PubMed ID: 38052232
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.
Chen J; Zhao D; Meng Q
Biomed Pharmacother; 2019 Aug; 116():108966. PubMed ID: 31102936
[TBL] [Abstract][Full Text] [Related]
18. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA UCA1 regulates proliferation and apoptosis in multiple myeloma by targeting miR-331-3p/IL6R axis for the activation of JAK2/STAT3 pathway.
Li JL; Liu XL; Guo SF; Yang Y; Zhu YL; Li JZ
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9238-9250. PubMed ID: 31773675
[TBL] [Abstract][Full Text] [Related]
20. NR2C2-uORF targeting UCA1-miR-627-5p-NR2C2 feedback loop to regulate the malignant behaviors of glioma cells.
Fan Z; Zheng J; Xue Y; Liu X; Wang D; Yang C; Ma J; Liu L; Ruan X; Wang Z; Liu Y
Cell Death Dis; 2018 Dec; 9(12):1165. PubMed ID: 30518750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
